OracleBio data quantifying ICOS and FoxP3 dual IHC in clinical HCC samples is presented on a collaborative poster at the AACR 2020 Virtual Annual Meeting.
The poster, produced in collaboration with Kymab and the National Taiwan University Hospital, explores the clinical significance of ICOS expression and Treg content in hepatocellular carcinoma (HCC). The poster is entitled ‘High ICOS/FOXP3 Tregs Content in the Tumor Microenvironment is Associated with Poorer Survival in Patients with Hepatocellular Carcinoma’ and is available to view and download by clicking on the poster below:
Background: Immunotherapy targeting co-stimulatory receptors of T cells is under active clinical investigation. Inducible co-stimulator (ICOS) is an important co-stimulatory receptor on effector T cells (Teffs) that also promotes tumor growth due to its high expression on regulatory T cells (Tregs). Human IgG1 anti-ICOS therapeutic antibodies may therefore induce antitumor immunity by stimulating ICOSLow Teffs and depleting ICOSHigh Tregs. This study explored the clinical significance of ICOS expression and Treg content in hepatocellular carcinoma (HCC).
Patients and Methods: We collected tumor tissues from HCC patients who received curative hepatectomy at the National Taiwan University Hospital, Taipei, Taiwan. Dual immunohistochemistry (IHC) was performed to evaluate the expression of ICOS and Foxp3. The cell density and distances between single- and dual-expressing cells in the tumor center, margin, and the peritumor area were quantitated by digital pathology. Associations between clinical outcome or clinical metadata and ICOS/Foxp3 expression were analyzed.
Results: A total of 142 patients (male: female= 112: 30, median age of 61.0 years) were enrolled. Among them, 87 (61.3%) had chronic hepatitis B virus (HBV) infection, 33 (23.2%) had chronic hepatitis C (HCV) infection, and 22 (15.5%) had no HBV/HCV infection. In this cohort, low AFP level (< 20 ng/ml) and early stage, but not age, gender, or viral etiology, were significantly associated with improved overall survival (OS). However, the density of ICOS+Foxp3+ cells and the ratio of ICOS+Foxp3+/total Foxp3+ cells were significantly higher (p<0.001) in the tumor center than in the peritumor area especially in viral-related HCC. Similarly, patients with a high ratio of ICOS+Foxp3+/total Foxp3+ cells (p=0.074) or with high ICOS expression (p<0.05) in the tumor center were associated with a shorter OS. Finally, a shorter distance between ICOS+Foxp3+ cells and ICOS+Foxp3– cells in the tumor center was significantly associated with a shorter OS (p<0.05) suggesting active immunosuppression of ICOS+ Tregs on ICOS+ Teff cells.
Conclusions: A high proportion of Tregs in HCC tumors expresses ICOS, implying a strong immunosuppressive environment. Importantly, high ICOS expression in HCC tumors, a high ratio of ICOS+Foxp3+/total Foxp3+ cells and a shorter distance between ICOS+ Tregs and other ICOS+ cells are all associated with a poor OS, suggesting that targeting ICOS in this indication may provide clinical benefit (This work is partly supported by MOST 108-2314-B-002-073).
Want to find out more about OracleBio’s quantitative digital pathology services? Contact us today to schedule a meeting.
To keep up to date with all OracleBio news and blogs, please follow us on LinkedIn and Twitter: